- Antigen-presenting cells and inflammatory response
- Pharmacogenomics
- Physiology of Inflammatory processes
- Experimental Oncology
- Genetics of Lymphoid Malignancies
- Hematological genetics
- Molecular Genetics of Hemophilia
- Haemostasis and thrombosis
- Immunology of Respiratory Diseases
- Experimental immunology
- Innate immunity
- Onco-immunology
- Mutagenesis
- Pathogenesis and inmunology of infectious processes
- Pathogenesis of viral infections
- Trombosis Experimental e Inmunobiología de la Inflamación
PATHOGENESIS AND IMMUNOLOGY OF INFECTIOUS PROCESSES
Our laboratory has been working for several years on the pathogenesis of Hemolytic Uremic Syndrome (HUS), and the development of treatments and vaccines, since up to date there is none is of these. HUS is an endemic disease In Argentina, with the highest annual incidence in the world: 10-12 / 100,000 children under 5 years of age. Enterohemorrhagic Escherichia coli (EHEC) O157: H7 is the main etiologic agent, and Shiga toxin (Stx) is absolutely necessary for progression to HUS. Given that 10-15% of patients infected with EHEC evolve to HUS, our hypothesis has been that in addition to the bacteria's own factors (virulence factors, infective dose, etc.), the host factors during pathogen-immune response interaction defines the outcome of the infection to self-contained or to severe, systemic forms. It is estimated that 35-40% of HUS patients will have renal or neurological sequelae, of different degrees, for life.
Thus, we have focused on the study of the systemic inflammatory and anti-inflammatory response, and the local response in the intestinal mucosa. In both cases we analyze the innate and the specific (or adaptive) immune responses.
Based on the hypothesis that the protective capacity of specific antibodies could avoid HUS outcome, we have engineered a highly effective immunogen at developing specific antibodies against the Stx toxin and generating protection in the host. This product has been patented and is the basis for the development of a treatment for HUS based on equine antibodies currently (Phase III)
In parallel, we have analyzed bacterial biology and the regulation of virulence factors during the interaction with the intestinal microbiome.
We have developed different murine models of HUS, based on Stx intoxication and EHEC infection, which are extremely useful in modeling the human disease. We also study pediatric patients with HUS during the acute phase or after a recovery period.
Chair: Marina S Palermo, PhD. CONICET Senior researcher.
E-mail: marinasandrapalermo@gmail.com
- Maria Victoria Ramos, PhD. CONICET Associate researcher.
E-mail: toresani7@hotmail.com
- Romina J Fernández-Brando, PhD. CONICET Assistant researcher.
E-mail: fernandezbrandoromina@gmail.com
- BSc Alan Mauro Bernal. PhD student – CONICET. alanmbernal@gmail.com
- BSc Gabriela Alejandra Fiorentino. PhD student – CONICET. gabriela.fiorentino85@gmail.com
- BSc Fernando Nicolas Sosa. PhD student – CONICET. fernsosa94@gmail.com
MODULATION OF THE INFLAMMATORY MECHANISMS INVOLVED IN HUS DEVELOPMENT.
Main responsible: Ramos, PhD.
- Analysis of the mechanisms involved in the NETosis triggered by Shiga toxin in human neutrophils.
- Analysis of the relevance of NETs in an HUS murine model.
- Analysis of the effects of the anti-inflammatory cytokine IL-10 in Hus development.
PROBIOTICS AND PREBIOTICS AS A PROPHYLACTIC OR THERAPEUTIC TREATMENT IN SHIGA TOXIN-PRODUCING ESCHERICHIA COLI INFECTIONS.
Main responsible: Fernández- Brando, PhD.
- Direct effects on bacterial pathogenicity and modulatory effects on the immune response on a mouse model.
STUDY OF THE INTESTINAL IMMUNE RESPONSE AND BACTERIAL PATHOGENESIS.
Main responsible: Palermo, PhD.
- Study of the bacterial-host interaction in early stages of EHEC/STEC infections. Implications on pathogenesis and bacterial transmission to new hosts.
- Development of a mouse model of incremental Shiga toxin 2 (Stx2) intoxication for testing new therapeutic agents against Hemolytic Uremic Syndrome (HUS). Mejias MP, Fernandez-Brando RJ, Ramos MV, Abrey-Recalde MJ, Zotta E, Meiss R, Palermo MS, Current Pharmaceutical Design, 2016;22(34):5294-5299.
- Development of camelid single chain antibodies against Shiga toxin type 2 (Stx2) with therapeutic potential against Hemolytic Uremic Syndrome (HUS). Mejías MP; Hiriart Y; Lauché C, Fernández-Brando RJ; Pardo R; Bruballa AC; Ramos MV; Goldbaum FA; Zylberman V; Palermo MS. Scientific reports, 2016 Apr 27;6:24913. doi: 10.1038/srep24913.
- Induction of Neutrophil Extracellular Traps in Shiga Toxin-Associated Hemolytic Uremic Syndrome. Ramos MV, Mejias MP, Sabbione F, Fernandez-Brando RJ, Santiago AP, Amaral MM, Exeni R, Trevani AS, Palermo MS. J Innate Immun. 2016;8(4):400-11. doi: 10.1159/000445770. Epub 2016 May 28.
- Immunization with BLS-Stx2B chimera totally protects dams from early pregnancy loss induced by Shiga toxin type 2 (Stx2) and confers anti-Stx2 immunity to the offspring. Sacerdoti F, Mejías MP, Bruballa AC, Alvarez RS, Amaral MM, Palermo MS, Ibarra C. Vaccine 34 (2016) 4732–4737. http://dx.doi.org/10.1016/j.vaccine.2016.07.049 2017.
- Immune Response in Calves Vaccinated with Type Three Secretion System Antigens and Shiga Toxin 2B Subunit of Escherichia coli O157:H7. Martorelli L, Garbaccio S, Vilte DA, Albanese AA, Mejías MP, Palermo MS, Mercado EC, Ibarra CE, Cataldi AA. PLoS One. 2017 Jan 3;12(1):e0169422. doi: 10.1371/journal.pone.0169422.
- Microbiological and serological control of Escherichia coli O157: H7 in kindergarten staff in Buenos Aires city and suburban areas. Fernández-Brando RJ, Amaral MM, Ciocchini AE, Bentancor LV, Trelles JA, Da Rocha M, Landriel M, Ugarte M, Briones G, Ibarra C, Palermo MS. Medicina (B Aires). 2017;77(3):185-190.
- Soluble CD40 Ligand and Oxidative Response Are Reciprocally Stimulated during Shiga Toxin-Associated Hemolytic Uremic Syndrome. MJ. Abrey Recalde, RS. Alvarez , F Alberto, MP. Mejias, MV Ramos, RJ Fernandez Brando, AC. Bruballa, RA Exeni,L Alconcher, CA Ibarra , MM. Amaral and MS Palermo.Toxins 2017, 9, 331; doi:10.3390/toxins9110331. 2018.
- Immunization of pregnant cows with Shiga toxin-2 induces high levels of specific colostral antibodies and lactoferrin able to neutralize E. coli O157:H7 pathogenicity. A Albanese, F Sacerdoti, E. A Seyahian, M M Amaral, G Fiorentino, R Fernandez Brando, D A. Vilte, EC. Mercado, M S. Palermo, A Cataldi, E Zotta, C Ibarra. Vaccine 2018; 20;36(13):1728-1735. doi: 10.1016/j.vaccine.2018.02.060
- Efficacy of calves vaccination with recombinant Intimin, EspB and Shiga toxin 2B after experimental challenge with Escherichia coli O157:H7. L Martorelli, N Galimano, GA Fiorentino, DA. Vilte, S Garbaccio, AA Albanese, S Barth, C Menge, CE Ibarra, MS Palermo, AA Cataldi. Vaccine. 2018 May 25. pii: S0264-410X(18)30679-0.
- Relevance of Bacteriophage 933W in the development of the Hemolytic Uremic Syndrome (HUS). ME Del Cogliano, A Pinto, J Goldstein, E Zotta, F Ochoa, RJ Fernández-Brando , M Muniessa, PD Ghiringhelli, MS Palermo and LV Bentancor. Front Microbiol. 2018 Dec 13;9:3104. doi: 10.3389/fmicb.2018.03104. eCollection 2018.a
- Human recombinant Fab fragment neutralizes Shiga toxin type 2 cytotoxic effects in vitro and in vivo. D Luz, MM Amaral, F Sacerdoti, AM Bernal, MS Palermo, C Ibarra, RM Piazza. Toxins (Basel). 2018 Dec 2;10(12). pii: E508. doi: 10.3390/toxins10120508.
- Pathogenic role of inflammatory response during Shiga toxin-associated Hemolytic Uremic Syndrome (HUS) .Ramon Exeni, Romina Fernandez-Brando, Adriana Santiago, Gabriela Fiorentino, Andrea M Exeni, Maria Victoria Ramos, Marina Sandra Palermo. Pediatric Nephrology, 2018;33(11):2057-2071. doi: 10.1007/s00467-017-3876-0. 2019.
- Cytokines use different intracellular mechanisms to upregulate the membrane expression of CX3CR1 in human monocytes. Panek CA, Bruballa AC, Pineda GE, De Brasi C, Fernández-Brando RJ, Mejías MP, Ramos MV, Palermo MS. Mol Immunol. 2019 Feb 15;108:23-33. doi: 10.1016/j.molimm.2019.01.003
- Consequences of the Lack of IL-10 in Different Endotoxin Effects and its Relationship With Glucocorticoids. Córdoba-Moreno MO, Todero MF, Fontanals A, Pineda G, Daniela M, Yokobori N, Ramos MV, Barrientos G, Toblli JE, Isturiz MA, Rearte B. Shock. 2019 Aug;52(2):264-273. doi: 10.1097/SHK.0000000000001233. 2020.
- Role of Shiga Toxins in Cytotoxicity and Immunomodulatory Effects of Escherichia coli O157:H7 during Host-Bacterial Interactions in vitro. Bruballa AC, Shiromizu CM, Bernal AM, Pineda GE, Sabbione F, Trevani AS, Bentancor LV, Ramos MV, Fernández-Brando RJ, Muñoz MJ, Palermo MS. Toxins (Basel). 2020 Jan 14;12(1). pii: E48. doi: 10.3390/toxins12010048.
- Mechanisms involved in the adaptation of Escherichia coli O157:H7 to the host intestinal microenvironment. Fernandez-Brando RJ, McAteer SP, Montañez-Culma J, Cortés-Araya Y, Tree J, Bernal A, Fuentes F, Fitzgerald S, Pineda GE, Ramos MV, Gally DL, Palermo MS. Clin Sci (Lond). 2020 Dec 23;134(24):3283-3301. doi: 10.1042/CS20200971. 2021.
- Preservation of protective capacity of hyperimmune anti Stx2 bovine colostrum against EHEC O157:H7 pathogenicity after pasteurization and spray-drying processes.N. Garimano, L.I. Diaz Vergara, A.D. Kim, E.E Badin, S. Sodero, A. M. Bernal, D. D. Gonzalez, M. M. Amaral, A. R. Lespinard, C. Porporatto, M. A. Montenegro, M. S. Palermo, M. Larzabal, A. A. Cataldi, C. Ibarra, F. Sacerdoti. Journal of Dairy Science, 2021. May;104(5):5229-5238. doi: 10.3168/jds.2020-19709.
- ABSENCE OF INTERLEUKIN-10 REDUCES PROGRESSION OF SHIGA TOXIN INDUCED HEMOLYTIC UREMIC SYNDROME.GE Pineda, B Rearte, MF Todero, AC Bruballa, AM Bernal, RJ Fernandez-Brando, MA Isturiz,E Zotta, C DirneyAlba-Soto, MS Palermo, MV Ramos. Clin Sci (Lond). 2021, Feb 12;135(3):575-588. doi: 10.1042/CS20200468.
- DIFFERENTIAL OUTCOME BETWEEN BALB/C AND C57BL/6 MICE AFTER Escherichia coli O157:H7 INFECTION IS ASSOCIATED TO A DISSIMILAR TOLERANCE MECHANISM. AM Bernal, RJ Fernández-Brando, AC Bruballa, GA Fiorentino2, GE Pineda, E Zotta, M Vermeulen, MV Ramos, M Rumbo, MS Palermo. Infection & immunity, 2021, Apr 16;89(5):e00031-21. doi: 10.1128/IAI.00031-21
Book chapters
- Pathogenic Escherichia coli in Latin America, 2016, Ed. Alfredo Torres: Chapter 11: Palermo, MS, Flores J, Paredes-Paredes M. Therapeutics and vaccines against pathogenic E. coli.
- Nefrología Pediátrica, 2018, Ed. García Nieto Victor, Exeni Ramón A, Medeiros Mara, Santos Fernando, Editorial de la Universidad de Oviedo, España. Capítulo 5: El sistema Complemento. MS Palermo, C Dos Santos, A Sanchez-Luceros. Capítulo 12: SINDROME UREMICO HEMOLITICO. RA Exeni,A M Exeni, MS Palermo.